表观遗传编辑技术来了!Chroma携1.25亿美元融资亮相,David Liu是科学创始人之一


On November 17, chroma medicine, which developed epigenetic editing technology, announced its start-up with a financing of US $125 million. Chroma’s seed round financing comes from Atlas venture, newpath partners and sofinnova partners. The round a financing is led by cormorant asset management, followed by cassin capital, Janus Henderson investors, Omega funds and other institutions. These funds will be used for the sustainable development of the company’s epigenetic editing platform and the promotion of product pipeline.
2 Likes

Let’s work together to find the pathogenesis.

1 Like

Awesome find!

“ “Epigenetic editing provides fundamental mechanistic advantages over other genomic medicine approaches,” said Vic Myer, Ph.D. “First, by mimicking cells’ existing mechanism for regulating gene expression, it enables complete control of the target without activating unpredictable DNA repair pathways. Second, epigenetic editing opens the possibility of pursuing targets in the genome that are difficult to access with other therapeutic approaches, offering hope to patients suffering from serious illnesses.”

Looks promising!!

2 Likes

https://mp.weixin.qq.com/s/Zx8GYmm6prJB-YDk48QlxQ I saw an article on cell today. Is it related to axo’s research?

1 Like